Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZBTB46-siRNA
- Development stage
- Preclinical
- Lead developer
- Emory University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
ZBTB46-siRNA is a small interfering RNA (siRNA) designed to silence the expression of the Zinc finger and BTB domain containing 46 (ZBTB46) transcription factor. ZBTB46 is a member of the BTB-ZF protein family and is typically expressed in endothelial cells (ECs) and dendritic cells. In the context of vascular biology, ZBTB46 is down-regulated in areas of disturbed flow, which are prone to atherosclerosis. Silencing ZBTB46 with siRNA leads to a significant reduction in the expression of the anti-apoptotic protein BCL2A1, thereby increasing the susceptibility of endothelial cells to apoptosis and exacerbating injury from oxidative stress. This tool is primarily used in research to investigate the molecular mechanisms of endothelial activation and the pathogenesis of atherosclerosis.
- Other names
- ZBTB46 small interfering RNAZBTB-46 small interfering RNAZBTB 46 small interfering RNA
02
Targets
ZBTB46 (Zinc finger and BTB domain-containing protein 46)
Beyond the preview
Go deeper on ZBTB46-siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZBTB46-siRNA.